FDA Inspection 1192023 — Xeris Pharmaceuticals, Inc.
The FDA completed an inspection of Xeris Pharmaceuticals, Inc. on November 16, 2022 in Chicago, IL. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 16, 2022
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Chicago, IL (United States)
Additional Details
Sponsor, Contract Research Organization